Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's Disease

• Status: Completed
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate effectiveness of 2 months antibiotic course of Azithromycin combined with Metronidazole compared with 2 months antibiotic course of Metronidazole alone.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Prof. Arie Levine
• Treatments: Azithromycin; Metronidazole

Criteria

Inclusion Criteria:

1. Children 5-17 years of age.

2. Diagnosis of active Crohn's Disease.4. Patients with a PCDAI≥10 ≤40 (mild to moderate disease).

3. Have involvement of the colon and/or terminal ileum.

4. Disease defined as L1, L2, L3 or any of the above and may have gastric, duodenal or esophageal disease (L4a) according to the Paris classification for site of disease.

5. The CRP ≥ 0.6 mg/dL.

6. Duration of disease since diagnosis < 3 years.

7. Negative stool culture, Clostridium Difficile Toxin from current flare.

Exclusion Criteria:

1. Duration of disease since diagnosis > 3 years.

2. Positive stool culture or O&P last 30 days.

3. Presence of clostridium difficile toxin in stool.

4. Azithromycin or Metronidazole allergy or known intolerance.

5. Diagnosis of IBD -U.

6. Presence of macroscopic disease involving the proximal ileum or jejunum (L4b).

7. Continuous macroscopic disease of the colon appearing as typical ulcerative colitis and Crohns diagnosed only by focality or granuloma on biopsies.

8. Presence of extraintestinal manifestations (such as arthritis, uveitis, or sclerosing cholangitis).Apthous lesions of mouth can be included.

9. Presence of fibrostenotic disease (strictures with prestenotic dilatation).

10. Presence of penetrating disease (fistulas or abscess).

11. Presence of current perianal disease defined as fistula or abscess.

12. Patients receiving concurrent corticosteroids or biologics.

13. Patients who have received steroids in the past 14 days.

14. Immune deficiency (CGD, GSD1, IL10R etc).

15. Known allergy or intolerance to any of the study medications.

16. Concurrent diseases such as hepatitis, ALT >2 times UNL, renal failure.

17. Pregnancy.

18. Patients with known heart disease.

19. Prolonged QTc by E.C.G at baseline.

20. Patient after surgical resection.